



Journal of
Clinical and Experimental Hematopathology

JCEHに掲載されるメリット

日本リンパ腫学会編集委員会

JCEHはMEDLINE掲載誌かつIF付与雑誌

MEDLINE

米国国立医学図書館が作成する生命科学分野図書データベース(約4300誌)

Web of Science Core Collection (WSCC)

クラリベイト社が認定する影響力のある学術誌:
Impact factorが付与 (約21000誌)

- JCEHはいずれのデータベースにも収録されています
- Impact factor (2022): **1.5**

JCEHはオープンアクセスジャーナル

オープンアクセス: インターネット経由で世界中の誰でも無料で論文本文のPDFにアクセス可能
→研究成果を迅速かつ広範に届けることができます

APC (掲載料)(2024年掲載分より): 一般的なオープンアクセスジャーナルに比べて格安 (特に学会会員)

70,000円 (税別)* (会員)

*非会員は150,000円 (税別), Letter to the editorは40,000円 (税別)

症例報告の抄録がPubMedに掲載

- 近年症例報告がletter形式で掲載になる場合が増えている
- この場合PubMedに抄録が掲載されない
- JCEHの症例報告のほとんどはfull article扱い

Case Reports > J Clin Exp Hematop. 2023 Mar 28;63(1):43-48. doi: 10.3960/jslrt.22041.

Epub 2023 Mar 26.

Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia

Takahiro Suyama¹, Masao Hagihara², Naruaki Matsui³, Rie Irie³, Yoshiyuki Osamura³, Tetsuo Sakai¹, Shouichi Watanabe¹, Shintarou Umemoto¹, Naoki Miyao¹

Affiliations + expand

PMID: 36843069 PMCID: [PMC10158722](#) DOI: [10.3960/jslrt.22041](#)

[Free PMC article](#)

Abstract

We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib treatment was discontinued and drainage was performed to regress the effusion. The major molecular response (MMR) was thus lost. The patient did not tolerate nilotinib treatment, but bosutinib was successful in restoring MMR. During these clinical courses, the patient suffered from a recurrence of EBL, which was treated with rituximab-based chemotherapy. The PE sample just before the 3rd cycle of chemotherapy revealed the proliferation of CD57-positive T cells, along with the disappearance of lymphoma cells. Anti-tumor immunity may have been activated following the immunochemotherapy in the undisturbed immunological environment when both EBL and CML almost regressed. After four cycles of R-CVP therapy, the patient has been in remission for 16 months and no longer requires drainage.

Keywords: CD57 positive T cell; HHV8-negative effusion-based lymphoma; anti-tumor immunity; dasatinib; pleural effusion.